Dr.
Jessica N. McAlpine
M.D.
Co-Division Head, Dr. Chew Wei MBBS [HK] FRCOG [ENG] Memorial Chair in Gynaecologic Oncology
Professor
Division of Gynaecologic Oncology
Biography
Dr. Jessica McAlpine was born and raised in Vancouver. She did her medical training in the US, returning in 2006 to take a position at UBC and BC Cancer. Dr. McAlpine has been appointed the Dr. Chew Wei Memorial Chair in Gynaecologic Oncology and Heads the Division of Gynaecologic Oncology with Dr. Sarah Finlayson. She is part of the OVCARE research team (British Columbia’s Gynecological Cancer Research group), Director of the OVCARE Tissue Bank and recipient of a CIHR New Investigator Award (2013-2018) and BC Cancer Foundations Clinician Scientist Award in (2016-2021). Her research focuses on molecular subtypes of endometrial, ovarian and vulvar cancers, and the prevention of ovarian cancers.
Teaching
Research Interests/Skills
Publications
McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak AK. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer, 2009. Dec 10;9:433. PMID: 20003286 |
Kortman U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O’Conner MJ, Huntsman DG, Wang Y, Gilks CB. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res, 2011 Feb 15; 17(4):783-91. PMID: 21097693 |
McAlpine JN, El-Hallani S, Lam SF, Kalloger SE; Luk M, Huntsman DG, MacAulay, C, Gilks CB, Miller DM, Lane PM. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol Oncol 2011 Mar; 120(3):385-92. PMID: 21237503 |
McAlpine JN, Vermorken JB, Wenzel LB. Survivorship as an element of clinical trials in ovarian cancer. Int J Gynecol Cancer 2011 May;21(4):788-92. PMID: 21543942 |
McAlpine JN, Gilks CB. Human epidermal growth factor receptor 2 overexpression and amplification in mucinous tumours of ovary Histopathology, 2011 Jun;58(7):1173-4. PMID: 21707717 |
Brotto L, Branco N, Dunkley C, McCullum M, McAlpine JN. Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study. J Obst Gynaecol Canada, 2012 Feb;34(2):172-8. PMID: 22340066 |
Brotto, L, Erskine Y, Carey M, Ehlen T, Finlayson S, Heywood M, Kwon J, Thomson S, Stuart G, McAlpine JN, Miller DM. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012 May;125(2):320-5. PMID: 22293042 |
McAlpine JN, Porter H, Kobel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012 May;25(5):740-50 PMID: 22282309 |
Tone A, Salvador S, Finlayson SJ, MD, Tinker AV, Kwon JS, Lee C, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J,Hoskins P, Stuart GC, Swenerton KD,Huntsman DG, Gilks CB, Miller DM, McAlpine, JN. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012 May;10(5):296-306. PMID: 22706539 |
Schrader I, Hurlburt J, Gilks CB, Huntsman DG, McAlpine JN. Germline mutations in BRCA1 and BRCA2 in ovarian cancer: utility of a histology-based referral strategy. Obst Gynecol, 2012 Aug;120 (2 Pt 1):235-40. PMID: 22776961 |
McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012 Sep; 228(1):20-30. PMID: 22653804 |
Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013 Sep;231(1):21-34. PMID: 23780408 |
Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff B, Kalloger SE, Senz J, Yang W, Steed H, Ferguson S, Teoman A, Allo G Garcia J, Schoolmeester JK, Shaw P, Bakkum-Gamez J, Tinker A, Bowtell D, Huntsman DG, Gilks CB, McAlpine JN. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013 Jan 1;229(1):111-20. PMID: 22899400 |
Teng FF, Kalloger SE, Brotto, LA, McAlpine JN. Determinants of quality of life in ovarian cancer survivors: A pilot study. J Obstet Gynaecol Can. 2014 Aug 31;36(8):708-15. PMID: 25222166 |
McAlpine JN, Hanley GE, Woo MMM, Tone AE, Rozenberg N, Heywood MS, Kaye SH, Kwon JS, Ehlend TG, Carey MS, Mazgani M, Stuart GC, Swenerton KD, Gilks CB, Finlayson SJ, Huntsman DG, Miller DM. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol. 2014 May;210(5):471.e1-11. PMID: 24412119 |
Gleicher N, McAlpine JN, Gilks CB, Kushnir VA, Lee HJ, Wu Y-G, Lazzaroni-Tealdi E, Barad DH. Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers. PLOS One 2014 Jul 18;9(7):e102370. PMID: 25036526 |
Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melynk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. TITAN: Inference of copy number architectures in clonal cell populations from tumor whole genome sequence data. Genome Res. 2014 Nov 1;24(11):1881-93. PMID: 25060187 |
Joly F, McAlpine JN, Nout RA, Avall-Lundqvist E, Friedlander ML, on behalf of the Gynecologic Cancer Intergroup (GCIG). Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action! Int J Gynecol Cancer. 2014 Nov 1;24(9):1693-9. PMID: 25340294 |
McAlpine JN, Greimel E, Brotto LA, Nout RA, Shash E, Avall-Lundqvist E, Friedlander ML, Joly F, on behalf of the Gynecologic Cancer Intergroup (GCIG). Quality of Life research in endometrial cancer: what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic Cancer InterGroup Symptom Benefit Working Group brainstorming session, Leiden 2012. Int J Gynecol Cancer. 2014 Nov 1;24(9):1686-92. PMID: 25340293 |
McAlpine JN, Lisonkova S, Joseph KS, McComb P. Pelvic inflammation and the pathogenesis of ovarian cancer: a cohort study. Int J Gynecol Cancer. 2014 Oct 1;24(8):1406-13. PMID: 25191876 |
Singh N, Leen SL, Han G, Faruqi A, Kokka F, Rosenthal A, Jiang J, Kim R, McAlpine JN, Gilks CB. Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss. Am J Surg Pathol. 2015 Jan 1;39(1):52-60. PMID: 25025443 |
Kwon JS, McAlpine JN, Hanley G, Finlayson S, Cohen T, Miller DM, Gilks CB, Huntsman DG. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015 Feb 1;125(2):338-45. PMID: 25568991 |
Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, Menon U, Fasching PA, Doherty JA, Modugno F, Schildkraut JM, Rossing MA, McAlpine JN, Huntsman D, Wu AH, Berchuck A, Pike MC, Pharoah PDP. Population distribution of lifetime risk of ovarian cancer in the United States Cancer Epidemiol Biomarkers Prev. 2015 Apr 1;24(4):671-6. PMID: 25623732 |
Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015 May 19;15(1):1. PMID: 25986173 |
McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015 May 31;137(2):306-10. PMID: 25636458 |
Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015 Jul 14;113(2):299-310. PMID: 26172027 |
Nelson BH, McAlpine JN. The more tumors change, the more they stay tame: Do T cells keep POLE ultramutated endometrial carcinomas in check? Gynecol Oncol. 2015 Jul;138(1):1. PMID: 26072691 |
Burleigh A, Talhouk A, Gilks CB, McAlpine JN. Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. Gynecol Oncol. 2015 Jul 31;138(1):141-6. PMID: 25870916 |
Hoang LN, McConechy MK, Kobel M, Anglesio M, Senz J, Maassen M, Kommoss S, Meng B, Postovit L, Kelemen LE, Staebler A, Brucker S, Kramer B, McAlpine JN, Gilks CB, Huntsman DG, Lee CH. Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma. Int J Gynecol Cancer. 2015 Sep 1;25(7):1187-93. PMID: 26166557 |
Fujiwara K, McAlpine JN, Lheureux S, Matsumura N, Oza AM. Paradigm shift in the management strategy for epithelial ovarian cancer. Am Soc Clin Oncol Educ Book. 2016;35:e247-57. PMID: 27249730 |
Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson, SE, Kobel M, Soumelian V, Wesa M, Cameron, A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu, EG, McAlpine JN. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol. 2016 Apr 30;141(1):148-54. PMID: 26854651 |
McAlpine JN, Tone AA, Hanley GE. Opportunistic salpingectomy: we chose to act, not wait. J Obstet Gynaecol Can. 2016 May;38(5):425-7. PMID: 27261215 |
McConechy MK, Talhouk A, Leung S, Chiu D, Yang W, Senz J, Reha-Krantz LJ, Lee CH, Huntsman DG, Gilks CB, McAlpine JN. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin Cancer Res. 2016 Jun 15;22(12):2865-73. PMID: 26763250 |
Roth A, McPherson A, Laks E, Biele J, Yap D, Wan A, Smith MA, Nielsen CB, McAlpine JN, Aparicio S. Bouchard-Cote A, Shah SP. Clonal genotype and population structure inference from single-cell tumor sequencing. Nat Methods. 2016 Jul:13(7);573-6. PMID: 27183439 |
McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice LM, Khattra J, Smith MA, Nielsen CB, Mullaly SC, Kalloger S, Karnezis A, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall AJ, Marra MA, Bouchard-Cote A, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016 Jul;48(7):758-67. PMID: 27182968 |
Cheng AS, Karnezis AN, Jordan S, Singh N, McAlpine JN, Gilks CB. Immunostaining allows for accurate subclassification of vulvar squamous cell carcinoma into HPV-associated and HPV-independent cases. Int J Gynecol Pathol. 2016 Jul 1;35(4):385-93. PMID: 26630231 |
McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother’s cancer. Cancer. 2016 Sep 15;122(18):2787-98. PMID: 27308732 |
Talhouk A, Hoang LN, McConechy MK, Nakonechny Q, Leo J, Cheng A, Leung S, Yang W, Lum A, Kobel M, Lee CH, Soslow RA, Huntsman DG, Gilks CB, McAlpine JN. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment. Gynecol Oncol. 2016 Oct;143(1):46-53. PMID: 27421752 |
Hanley GE, McAlpine JN, Pearce CL, Miller D. The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol. 2016 Nov 1. pii: S0002-9378(16)30971-1. PMID: 27810554 |
McAlpine JN, Kim R. Akbari A, Eshraugh S, Knebel, K, Prigge E, Jordan S, Singh N, Miller DM, Reuschenbach M, Gilks CB. HPV-independent differentiated vulvar intraepithelial neoplasia (dVIN) is associated with an aggressive clinical course Int J Gynecol Path. 2017 Mar 17. [Epub ahead of print] PMID: 28319571 |
Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncolo Res Pract. 2016 Dec 13;3:14. PMID: 27999680 |
McAlpine JN, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 2018. Jan 17. PMID: 29344951 |
Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017 Mar 1;123(5):802-813. PMID: 28061006 |
Hoang LN, Kinloch MA, Leo JM, Grondin K, Lee CH, Ewanowich C, Kobel M, Cheng A, Talhouk A, McConechy M, Huntsman DG, McAlpine JN, Soslow RA, Gilks CB. Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. Am J Surg Pathol. 2017 Feb;41(2):245-252. PMID: 28079598 |
Karnezis AN, Leung S, Cheng A, Miller D, Talhouk A, Gilks CB, McAlpine JN. HPV-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. Laboratory Investigation. 2017 Feb; 97: 293A-293A. PMID: 28257152 |
Hanley GE, McAlpine JN, Pearce CL, Miller D The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States Am J Obstet Gynecol. 2017 Mar;216(3):270.e1-270.e9. PMID: 27810554 |
Wang YW, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Karnezis AN, Shumansky K, Siu C, McConechy MK, Li-Chang H, Tone A, Provencher D, de Laurantaye M, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mugall A, Moore R, Marra M, Gilks CB, Mes-Masson A, McAlpine JN, Aparicio S, Huntsman D, Shah SP. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nat Genet. 2017 Jun;49(6):856-865. PMID: 28436987 |
Proctor L, Pradhan M, Leung S, Cheng A, Lee CH, Soslow RA, Gilks CB, Talhouk A, McAlpine JN, Danielsen HE, Hoang LN. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer. Gynecol Oncol. 2017 Sep;146(3):596-602. PMID: 28647100 |
McAlpine JN, Leung SC, Cheng A, Miller D, Talhouk A, Gilks CB, Karnezis AN. Human papillomavirus (HPV) †independent vulvar squamous cell carcinoma has a worse prognosis than HPVâ€associated disease: a retrospective cohort study. Histopathology. 2017 Aug;71(2):238-246. PMID 28257152 |
Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG. Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? J Pathol. 2017 Sep;243(1):26-36. PMID: 28678427 |
Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, Kommoss F, Gilks CB, McAlpine JN. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 2017 Oct 14;3(4):279-293. PMID: 29085668 |
McAlpine JN, Kim SY, Akbari A, Eshragh S, Reuschenbach M, von Knebel Doeberitz M, Prigge ES, Jordan S, Singh N, Miller DM, Gilks CB. HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course Int J Gynecol Pathol. 2017 Nov;36(6):507-516. PMID: 28319571 |
Hanley GE, Rozenberg NMK, McAlpine JN. Risk-reducing Surgery in Women at Low Lifetime Risk of Developing Ovarian Carcinoma: Opportunistic Salpingectomy Clin Obstet Gynecol. 2017 Dec;60(4):758-770. PMID: 28957952 |
McAlpine JN, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses J Pathol. 2018. Jan 17 |
Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Kramer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN*, Talhouk A*. Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-based Case Series. Ann Oncol. 2018 May 1;29(5):1180-1188 |
Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C, Mitchell G. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention BMC Cancer. 2018 Mar 5;18(1):254. |
Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez |
Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl |
Kim SY, Tessier-Cloutier B, Cochrane, D, Britton H, Storness-bliss C, Lum A, Senz J, Lee CH, Hoang L, McAlpine J. Characterization of clear cell carcinoma of the endometrium: molecular subtype assignment to inform treatment decisions and improve outcomes. From Oral presentation at 39th Gynecologic Oncology of Canada, Victoria, BC, June 28-30, 2018 |
Hanley GE, Kwon JS, Finlayson SJ, Huntsman DG, Miller D, McAlpine JN Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada Am J Obstet Gynecol. 2018 Aug;219(2):172.e1-172.e8. PMID: 29852159 |
Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks B, Anglesio MS, Nelson BH, McAlpine JN Clin Cancer Res 2018. Dec6 Epub PMID: 30523022 |
Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, Burleigh A, Senz J, Yang W, McConechy M, Kommoss S, Brucker S, Talhouk A, Gilks CB, McAlpine JN. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol. 2019 Jun;153(3):487-495. doi: 10.1016/j.ygyno.2019.03.098. Epub 2019 Mar 25. pii: S0090-8258(19)30271-9 PMID: 30922603 |
Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks B, Anglesio MS, Nelson BH, McAlpine JN. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clin Cancer Res. 2019 Apr 15;25(8):2537-2548. (2018. Dec6 Epub) PMID: 30523022. |
Reijnen C, Kusters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, Brucker SY, Kwon JS, McAlpine JN, Pijnenborg JMA. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019 Jul;154(1):124-130. doi: 10.1016/j.ygyno.2019.03.097. Epub 2019 May 15. PMID: 31103324 |
McAlpine JN, Gilks CB. Precision medicine in endometrial cancer Gynecol Oncol. 2019 Sep;154(3):451-453. doi: 10.1016/j.ygyno.2019.08.001. No abstract available. PMID: 31472758 |
Zhang AW, O’Flanagan C, Chavez EA, Lim JLP, Ceglia N, McPherson A, Wiens M, Walters P, Chan T, Hewitson B, Lai D, Mottok A, Sarkozy C, Chong L, Aoki T, Wang X, Weng AP, McAlpine JN, Aparicio S, Steidl C, Campbell KR, Shah SP Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling. Nat Methods. 2019 Oct;16(10):1007-1015. doi: 10.1038/s41592-019-0529-1. Epub 2019 Sep 9. PMID: 31501550 |
O’Flanagan CH, Campbell KR, Zhang AW, Kabeer F, Lim JLP, Biele J, Eirew P, Lai D, McPherson A, Kong E, Bates C, Borkowski K, Wiens M, Hewitson B, Hopkins J, Pham J, Ceglia N, Moore R, Mungall AJ, McAlpine JN; CRUK IMAXT Grand Challenge Team, Shah SP, Aparicio S Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses. Genome Biol. 2019 Oct 17;20(1):210. doi: 10.1186/s13059-019-1830-0. |
A Leon-Castillo, H Briton, MK. McConechy, JN McAlpine, R Nout, S Kommos, SY Brucker, JW Carlson, E Epstein, TT Rau, T Bosse, DN Church, CB Gilks. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol. 2020 Mar;250(3):323-335. PMID: 31829442. doi: 10.1002/path.5372. Epub 2020 Jan 29 |
A Plotkin, B Kuzeljevic2, V.De Villa, E.F. Thompson, CB. Gilks, B Clarke, M Koebel, JN McAlpine Inter-laboratory concordance of ProMisE molecular classification of endometrial carcinoma based on endometrial biopsy specimens Int J Gynecol Pathololgy No. IJGP19-3986 |
L Proctor, L Hoang, J Moore, S Leung, B Gilks, E Thomson, D. Natesan, J. Chino, CB. GIlks, JN McAlpine. Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2020 Jan;30(1):100-106. doi: 10.1136/ijgc-2019-000793. Epub 2019 Nov 25. PMID: 31771962 |
A Leon-Castillo, E Gilvazquez, R Nout, Smit VT, JN McAlpine, M McConechy, S Kommoss, SY Brucker, JW Carlson, E Epstein, TT. Rau, R Soslow, R Ganesan, X Matias-Guiu, E Oliva, B Harrison, DN Church, B Gilks, T Bosse. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol. 2020 Mar;250(3):312-322. PMID: 31829447. |
Kim SY, Tessier Cloutier B, Leung S, Cochrane D, Britton H, Pina A, Storness-Bliss C, Farnell D, Huang L, Shum K, Lum A, Senz J, Lee CH, Gilks CB, Hoang L, McAlpine JN. Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification. Gyn Onc, July 2020. |
FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes. Clin Cancer Res. 2020 May 15. doi: 10.1158/1078-0432.CCR-19-4088. Online ahead of print. PMID: 32414751 |
Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. J Pathol. 2020 Jul 19. doi: 10.1002/path.5511. Online ahead of print. PMID: 32686114 |
Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020 Jul;63(4):417-431. doi: 10.5468/ogs.19169. Epub 2020 Jul 8.PMID: 32689770 |
Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clin Cancer Res. 2020 Jul 31:clincanres.1268.2020. doi: 10.1158/1078-0432.CCR-20-1268PMID: 32737030 |
For a full list of publications please contact Dr. McAlpine directly.
Grants
Canadian Institutes of Health Research (CIHR) |
Genomic disruption in high-grade serous ovarian carcinomas: Steady state or continuous drift? |
C |
Operating Grant |
$563,000 |
2011/06 – 2015/05 |
McAlpine JN, Shah SP |
Huntsman DG, Gilks CB |
||||||||||||
VGH Foundation |
Ovarian carcinoma from precursor lesion to prevention (PTP) |
$300,000.00 |
$300,000 |
2012/06 – 2015/06 |
Huntsman DG, McAlpineJN |
||||||||||||||
Gynecologic Cancer Initiative-Clinical Trials Group |
ProMisE-driven care in endometrial carcinoma-prospective trial |
C |
Project Grant |
$104,000 |
2019-2021 |
McAlpine JN |
Holloway C, Bachand F, Kumar A, Thompson E, Ko J, Ye A, Raziee H, Kwon J, Talhouk A |
||||||||||||
Canadian Institute of Health Research |
Pre-operative Risk Stratification in Endometrial Cancer to Inform Surgical Management |
C |
Project Grant |
$263,925 |
2020-2023 |
Talhouk, A McAlpine JN |
Gilks, CB Huntsman DG |
||||||||||||
Terry Fox Research Institute |
CIHR Team in Genomics of Frome Fruste Tumours: New vistas on cancer biology and treatment |
C |
Project Grant |
$7,500,000 |
2013/07 – 2019/07 |
Huntsman D, Aparicio S, Hansen C |
McAlpine J, Tinker A, Clarkson P, Schaeffer D |
||||||||||||
Carraresi Foundation OVCARE Research Grant |
Response to Primary Radiation in HPV-Associated and HPV-Independent Locally Advanced Vulvar Squamous Cell Cancers |
C |
|
$7,080 |
2017/06 – 2019/06 |
Lily Proctor |
McAlpine J |
||||||||||||
Canadian Institute of Health Research |
Multimodal optical imaging of the fallopian tubes |
C |
Impact Grant |
$378,675 |
2017/10 – 2020/09 |
Lane P |
MacAulay C, McAlpine JN |
||||||||||||
Canadian Cancer Society Research Institute |
The determinants of drug response in high grade serous ovarian cancer: a single cell population genetics approach |
C |
Impact Grant |
$1,250,000 |
2018/01 – 2023/12 |
Shah S & McAlpine J |
Aparicio S, Huntsman D, Bouchard-Cote A |
||||||||||||
Michael Smith Foundations for Health Research-REACH award |
Biologically informed ovarian cancer prevention: Promoting education and awareness |
C |
Current funding |
$10,000 |
2018/06 – 2019/06 |
McAlpine JNHuntsman DG |
Lee, S |
||||||||||||
Michael Smith Foundations for Health Research-Innovation to commercialization (I2C) |
Molecular classification for stratification and improved clinical management |
C |
Current funding |
$300,000 |
2018/07 – 2020/07 |
McAlpine JN |
Gilks CB, Aline T |
||||||||||||
Sumiko Kobayashi Marks Memorial OVCARE Research Grants supported by the VGH & UBC Hospital Foundation |
Refining the Clinical and Molecular Landscape of Vulvar Squamous Cell Carcinomas: Not a Single Disease Anymore |
C |
|
$19,678 |
2019/06 – 2021/05 |
Hoang LN |
McAlpineJN, Proctor L, Thompson E |
||||||||||||
Canadian Institute for Health Research-Project Grant |
The effectiveness and cost effectiveness of opportunistic salpingectomy for ovarian |
C |
|
$302,176 |
2019/07 – 2022/07 |
Hanley G |
McAlpineJN Huntsman DG, Gilks CB, Kwon J, Talhouk A, Kotsopoulos J |
||||||||||||
Canadian Institute of Health Research |
PrOTYPE: An Enabling Technology to Improve Ovarian Cancer Care |
C |
Proof of Principle I grant |
$154,829 |
2013/01 – 2015/12 |
Huntsman, DG |
McAlpine JN, Anglesio M |
Canadian Cancer Society Research Institute |
Contextual genomics: the foundation of subtype specific approaches to ovarian cancer control |
C |
Impact grant |
$1,996,690 |
2013/02 – 2018/01 |
Huntsman D |
McAlpine J,Shah S, Carey M, Gilks B, Miller D, Tinker A, Yong P, Morin R, Hoskins P, Cullis P, Anglesio M. |
British Columbia Cancer Foundation |
SMART cancer project: Shared access medicine, an approach to rare tumors |
C |
Research Award |
$264,100 |
2013/06 – 2015/05 |
McAlpine JN, Tinker AV |
|
BC Cancer Foundation (BCCF) Sarabjit Gill Memorial Fund |
Understanding intra-tumoral heterogeneity within endometrial cancers |
NC |
Research Award |
$80,000 |
2013/07 – 2015/06 |
McAlpine JN |
|
National Institute of Health |
Mechanisms of Prevention of Ovarian Cancer by Oral Contraceptives |
C |
Project Grant |
$52,704 |
2013/07 – 2015/07 |
Huntsman D, Pearce CL |
McAlpine JN, et al |
Terry Fox Research Institute |
CIHR Team in Genomics of Frome Fruste Tumours: New vistas on cancer biology and treatment |
C |
Project Grant |
$7,500,000 |
2013/07 – 2019/07 |
Huntsman D, Aparicio S, Hansen C |
McAlpine J, Tinker A, Clarkson P, Schaeffer D |
Cancer Research Society |
Circulation tumor DNA mutations in endometrial and ovarian cancer patients can be used to guide clinical management |
C |
Operating grant |
$119,147 |
2014/06 – 2016/05 |
McAlpine J |
Gilks CB, Huntsman D, Shah S |
Canadian Cancer Society Research Institute |
A population-based assessment of an ovarian cancer prevention program |
C |
Prevention research grant |
$324,612 |
2014/08 – 2017/07 |
McAlpine J, Huntsman D |
Coldman A, Gilks B, Miller D, Mitchell G |
Vancouver Coastal Health Research Institute |
Subclassification of vulvar cancer based on HPV status / p16 immunostaining: assessment |
C |
Innovation and Translation award |
$15,966 |
2015/09 – 2017/08 |
McAlpine JN, Gilks CB |
|
Canadian Cancer Society Research Institute |
Fixed tissue proteomics (FTP) applied to create a pragmatic clinical decision aid for endometrial cancer |
C |
Innovation grant |
$200,000 |
2016/02 – 2018/02 |
McAlpine J |
|
Canadian Institutes of Health Research |
PROMISE: A proactive molecular- based classification tool to improve endometrial cancer management |
C |
Proof of Principle I (POP1) grant |
$160,000 |
2016/06 – 2017/06 |
McAlpine J |
|
Michael Smith Foundation for Health Research |
Knowledge transfer of current molecular research in endometrial cancer to pathologists, gynecologists, family practitioners and other end-users in British Columbia |
C |
Collaborating and Convening Award |
$15,000 |
2017/01 – 2018/01 |
McAlpine J |
Schrader K, Miller D, Tinker A, Talhouk A, Huntsman, D, Gilks B |
University of British Columbia -Division of Gynecologic Oncology |
Practical methodologies for the identification of Synchronous Endometrial and Ovarian Carcinomas (SEOs) to improve outcomes |
C |
Research Award |
$20,000 |
2017/03 – 2018/02 |
McAlpine JN, Anglesio M |
Talhouk A, Hoang L, Britton H, Kale M. |
Carraresi Foundation OVCARE Research Grant |
Response to Primary Radiation in HPV-Associated and HPV-Independent Locally Advanced Vulvar Squamous Cell Cancers |
C |
|
$7,080 |
2017/06 – 2019/06 |
Lily Proctor |
McAlpine J |
Canadian Institute of Health Research |
Multimodal optical imaging of the fallopian tubes |
C |
Impact Grant |
$378,675 |
2017/10 – 2020/09 |
Lane P |
MacAulay C, McAlpine JN |
Canadian Cancer Society Research Institute |
The determinants of drug response in high grade serous ovarian cancer: a single cell population genetics approach |
C |
Impact Grant |
$1,250,000 |
2018/01 – 2023/12 |
Shah S & McAlpine J |
Aparicio S, Huntsman D, Bouchard-Cote A |
Michael Smith Foundations for Health Research-REACH award |
Biologically informed ovarian cancer prevention: Promoting education and awareness |
C |
Current funding |
$10,000 |
2018/06 – 2019/06 |
McAlpine JN Huntsman DG |
Lee, S |
Michael Smith Foundations for Health Research-Innovation to commercialization (I2C) |
Molecular classification for stratification and improved clinical management |
C |
Current funding |
$300,000 |
2018/07 – 2020/07 |
McAlpine JN |
Gilks CB, Aline T |
Gynecologic Cancer Initiative-Clinical Trials Group |
Molecular classification-drive care in Endometrial Cancer |
C |
|
$42,040 |
2019/01 – 2021/01 |
McAlpine JN |
Bachand F, Holloway C, Ko J, Kumar A, Kwon JS, Miller S, Raziee H, Talhouk A, Thompson E |
Sumiko Kobayashi Marks Memorial OVCARE Research Grants (supported by VGH & UBC Hospital Foundation) |
Refining the Clinical and Molecular Landscape of Vulvar Squamous Cell Carcinomas: Not a Single Disease Anymore |
C |
|
$19,678 |
2019/01 – 2021/01 |
Hoang LN |
McAlpine JN, Proctor L, Thompson E |
Sumiko Kobayashi Marks Memorial OVCARE Research Grants supported by the VGH & UBC Hospital Foundation |
Refining the Clinical and Molecular Landscape of Vulvar Squamous Cell Carcinomas: Not a Single Disease Anymore |
C |
|
$19,678 |
2019/06 – 2021/05 |
Hoang LN |
McAlpine JN, Proctor L, Thompson E |
Gynecologic Cancer Initiative-Clinical Trials Group |
ProMisE-driven care in endometrial carcinoma-prospective trial |
C |
|
$104,000 |
2019/07 – 2021/07 |
McAlpine JN |
Holloway C, Bachand F, Kumar A, Thompson E, Ko J, Ye A, Raziee H, Kwon J, Talhouk A |
Canadian Institute for Health Research-Project Grant |
The effectiveness and cost effectiveness of opportunistic salpingectomy for ovarian |
C |
|
$302,176 |
2019/07 – 2022/07 |
Hanley G |
McAlpine JN Huntsman DG, Gilks CB, Kwon J, Talhouk A, Kotsopoulos J |
Canadian Institutes for Health Research |
Personalizing Prevention Strategies in Endometrial Cancer |
C |
|
$100,000 |
2020/01 – 2021/01 |
Talhouk A |
McAlpine JN, Kwon J, Tinker A, Hanley G, Miller D |
Canadian Institute of Health Research |
Pre-operative Risk Stratification in Endometrial Cancer to Inform Surgical Management |
C |
|
$263,925 |
2020/07 – 2023/07 |
Talhouk A, McAlpine JN |
Gilks CB, Huntsman DG, Hanley G |
Projects
Awards
Selected Awards
University of British Columbia Faculty of Medicine- Mid-Career Excellence/Achievement, 2020
BC Cancer Foundation Clinician Scientist Award-Intertumoral heterogeneity in endometrial cancer $750,000 2016-2021.
University of British Columbia Faculty of Medicine -Excellence in Clinical or Applied Research 2016.
CIHR New Investigator Award. Genomic Disruption in High-Grade Serous Ovarian Carcinomas: Steady State or Continuous Drift? McAlpine JN $60,000/year 2012-2017.
Vancouver Coastal Health Research Institute In it For Life Mentored Clinical Scientist Award, 2008. PARP inhibitors in epithelial ovarian cancer: targeted molecular therapy in BRCA null phenotypes and mechanisms of resistance. $50,000/year 2008-2011.